Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review | Aplastic Anemia & MDS International Foundation Return to top.

Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review

Journal Title: 
Journal of Women's Health
Primary Author: 
Zhang B
Zhang B, Chu R, Huang C, Song X, Wang J, Li L, Xu Y, Ma Y
Original Publication Date: 
Wednesday, January 31, 2024

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired complement-mediated hemolytic disease characterized by intravascular hemolysis, thrombosis, smooth muscle dystonia, and so on. Thrombosis is the principal cause of death in PNH patients. During the perinatal period, pregnant PNH patients have increased morbidity and mortality with a heightened risk of complications, including significant preterm birth. The management of pregnancy complicated by PNH is difficult. Therefore, early diagnosis, standardized treatment protocols, and improving perinatal outcomes are crucial. However, there is a lack of consensus on treating patients with PNH during pregnancy. This article reviews 32 studies of pregnancy affected by PNH, focusing on the clinical presentation, diagnosis, and treatment strategies of PNH, to provide guidance for obstetricians on how to handle pregnant patients with PNH, and to offer academic support for the management of PNH patients. We found that Eculizumab has become the primary choice for treating PNH, effectively controlling intravascular hemolysis and reducing the frequency of blood transfusions necessary to stabilize the condition, with no severe threat to the safety of the mother and fetus.

Keywords: Eculizumab; anticoagulant therapy; intravascular hemolysis; paroxysmal nocturnal hemoglobinuria; pregnancy; thrombosis.

Bone Marrow Disease(s): 
  • paroxysmal nocturnal hemoglobinuria (PNH)
Share with